Absci Corporation (ABSI)
Absci Corporation operates in the Biotechnology industry of the Healthcare sector, headquartered in Vancouver, WA, US. The stock last traded at $9.10, down 3.29% on the session, giving a market capitalisation of $1.54B. On trailing twelve-month figures it carries a trailing P/E of -11.38, a net margin of -9740.7%. Its beta of 2.42 implies it has historically moved more than the broad market.
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
Absci Corporation is most often compared with the following Healthcare names: